🇺🇸 FDA
Patent

US 11771743

Methods for preventing or treating allergy by administering an IL-4R antagonist

granted A61KA61K2039/505A61K2039/545

Quick answer

US patent 11771743 (Methods for preventing or treating allergy by administering an IL-4R antagonist) held by REGENERON PHARMACEUTICALS, INC. expires Mon Sep 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Oct 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K2039/505, A61K2039/545, A61K38/1774, A61K39/00